A5052737906- Cancer-related Molecular Pathways
- IL-33, ST2, and ILC Pathways
- Genomics and Chromatin Dynamics
- Immune Response and Inflammation
- Gut microbiota and health
- Gastrointestinal motility and disorders
- Clinical Nutrition and Gastroenterology
- RNA Research and Splicing
- Immune Cell Function and Interaction
- PARP inhibition in cancer therapy
Indiana University South Bend
2022-2024
Indiana University School of Medicine
2022-2024
Mike and Josie Harper Cancer Research Institute
2024
University of Chicago
2023
Triple-negative breast cancer (TNBC) patients are treated with traditional chemotherapy, such as the taxane class of drugs. One drug, paclitaxel (PTX), can be effective in treating TNBC; however, many tumors will develop drug resistance, which lead to recurrence. In order improve patient outcomes and survival, there lies a critical need understand mechanism behind resistance. Our lab made novel observation that decreased expression Adenomatous Polyposis Coli (APC) tumor suppressor using...
Abstract Epithelial response to injury is coordinated through an intricate interaction with neuronal and myeloid cells, however the signaling modules involved are not well understood. In humans, somatic mutations in Tet methylcytosine dioxygenase 2 (TET2), a DNA demethylase, commonly observed during ageing cells known modulate inflammatory responses. Using mouse model that lacks TET2 (Tet2 ΔLysM), we show sympathetic neurons form nexus controls differentiation of enterochromaffin serotonin...
Abstract Patients with triple negative breast cancer (TNBC) are treated traditional chemotherapy, such as paclitaxel (PTX). Despite the efficacy of taxanes, many tumors will recur due to drug resistance. Therefore, need understand mechanism behind resistance is critical improve patient outcome and survival. Our lab was first show that loss Adenomatous Polyposis Coli (APC) tumor suppressor caused PTX in MDA-MB-157 human TNBC cell line. In absence APC, apoptosis induction decreased, measured...